Tokyo, Sept. 26 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059184) titled 'A study on the association between intestinal barrier function and disease onset' on Sept. 25.
Study Type:
Observational
Primary Sponsor:
Institute - Meiji Holdings Co., Ltd.
Condition:
Condition - Adults
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - The primary objective is to investigate which diseases are associated with the status of intestinal barrier function using large-scale community-based cohort data.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 45
years-old
Gender - Male and Female
Key inclusion criteria - Participants in the Tohoku Medical Megabank Project cohort study who took part in both the baseline survey and the second survey, with the baseline survey being the community-based cohort.
Key exclusion criteria - 1. Participants who requested to opt out of providing samples or information for this study during the information disclosure period.
2. Participants with a history of irritable bowel syndrome, ulcerative colitis, Crohn's disease, or colorectal cancer at the time of the baseline survey.
3. Participants who had taken within the previous two weeks antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), gastroprotective agents, metformin, immunosuppressants, or other medications reported to affect intestinal barrier function.
4. Participants deemed unsuitable as participants by the principal investigator.
Target Size - 2000
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 05 Month 28 Day
Date of IRB - 2025 Year 05 Month 28 Day
Anticipated trial start date - 2025 Year 09 Month 25 Day
Last follow-up date - 2025 Year 12 Month 26 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067698
Disclaimer: Curated by HT Syndication.
